Comparing serum biomarkers levels in the primary hepatic cancer group (group A) to the cirrhotic group (group B) and the control group (group C), significant statistical differences (P < 0.03 were observed between the malignant group and the benign group, whereas no statistically significant difference (P > 0.06) were present between the Liver cirrhosis group and the healthy control group, thus indicating higher serum AFP, CA19-9 and CEA mean levels in the cancer group as compared to the other two groups. The gene discussed is CEACAM5; the disease is cirrhosis of liver.